Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20496957 | 0.91 | HDAC1 (0.41) | HDAC1PIK3CAPIK3R1P2RX3HDAC2 | |
| SCHEMBL17087486 | 0.83 | PIK3CA (0.58) | HDAC1PIK3CAPIK3R1HDAC2MTOR | |
| SCHEMBL17078411 | 0.78 | CYP3A4 (0.44) | HDAC1PIK3CAPIK3R1CYP3A4SMN1; SMN2 | |
| SCHEMBL2396728 | 0.75 | CYP3A4 (0.45) | HDAC1PIK3CAPIK3R1CYP3A4MTOR | |
| SCHEMBL16542529 | 0.74 | HDAC1 (0.35) | HDAC1PIK3CAPIK3R1CYP3A4SMN1; SMN2 | |
| SCHEMBL17087371 | 0.73 | HDAC1 (0.63) | HDAC1PIK3CAPIK3R1HDAC2MTOR | |
| SCHEMBL2396926 | 0.73 | CYP3A4 (0.45) | HDAC1PIK3CAPIK3R1CYP3A4SMN1; SMN2 | |
| SCHEMBL1284135 | 0.73 | PIK3CA (0.44) | HDAC1PIK3CAPIK3R1HDAC2MTOR | |
| SCHEMBL2396757 | 0.72 | CYP3A4 (0.46) | HDAC1P2RX3CYP3A4PIK3CDSMN1; SMN2 | |
| SCHEMBL25232616 | 0.71 | PIK3CD (0.44) | HDAC1PIK3CAPIK3R1P2RX3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957270-B2 | Fused pyrimidine-based hydroxamate derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-01 | — | — | US | disclosed |
| US-9957270-B2 | Fused pyrimidine-based hydroxamate derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-01 | — | — | US | disclosed |
| US-9957270-B2 | Fused pyrimidine-based hydroxamate derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-01 | — | — | US | disclosed |
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-02-16 | — | — | US | disclosed |
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-02-16 | — | — | US | disclosed |
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-02-16 | — | — | US | disclosed |
| WO-2015137887-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | HDAC1, HDAC2, HDAC5 | HDAC1 1/4885PIK3CA 301/4885PIK3R1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.